Opendata, web and dolomites

COLOSTEO SIGNED

Nutraceutical supplementation based on colostrum for prevention of osteoporosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "COLOSTEO" data sheet

The following table provides information about the project.

Coordinator
PANEPISTIMIO THESSALIAS 

Organization address
address: ARGONAFTON FILELLINON
city: VOLOS
postcode: 38221
website: www.uth.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 828˙000 €
 EC max contribution 828˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2017
 Funding Scheme MSCA-RISE
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PANEPISTIMIO THESSALIAS EL (VOLOS) coordinator 207˙000.00
2    CENTRO DE ESTUDIOS SUPERIORES DE LA INDUSTRIA FARMACEUTICA SA ES (MADRID) participant 207˙000.00
3    CHRISTOS PAPADOPOULOS & SIA OE EL (KARDITSA) participant 207˙000.00
4    UNIVERSIDADE DO PORTO PT (PORTO) participant 207˙000.00

Map

 Project objective

Osteoporosis constitutes a major public health concern. The economic burden of osteoporotic fractures in EU is expected to increase 25% by 2025 compared to 2010. These estimates may indicate an inefficiency of current drugs for osteoporosis. Actually, the use of pharmacological agents for osteoporosis has been decreasing in EU, probably due to the reported side effects. Therefore, there is a need for innovative agents to reduce the burden of osteoporosis. Colostrum is a promising agent against bone loss since it has natural constituents that are directly involved in bone metabolism. As a nutraceutical, colostrum confers an advantage over pharmacological drugs since it can avoid side effects. However, the possibility of its use as a nutraceutical agent for osteoporosis have only received attention within the scientific community. The knowledge produced on the effects of colostrum on bone metabolism has not yet been transferred to the market because academic institutions lack on expertise to create a new product. On the other hand, industry has knowledge on product development, but lack expertise on research skills. In accordance, what hinders the creation of an innovative product based on colostrum for prevention of osteoporosis is the absence of an intersectorial collaboration. As consequence, there is a clearly gap between research on the matter and its application. COLOSTEO aims to fill in this gap by creating an intersectorial collaboration to exchange knowledge and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis. This aim will be achieved by bridging two academic with two industrial institutions that through intersectorial secondments will exchange knowledge, ideas and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis.

 Deliverables

List of deliverables.
Transfer of Knowledge Activities D3.3-4 Other 2020-01-30 19:57:47

Take a look to the deliverables list in detail:  detailed list of COLOSTEO deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLOSTEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COLOSTEO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

ROVER (2020)

RELIABLE TECHNOLOGIES AND MODELS FOR VERIFIED WIRELESS BODY-CENTRIC TRANSMISSION AND LOCALIZATION

Read More  

OPEN (2019)

Outcomes of Patients’ Evidence With Novel, Do-It-Yourself Artificial Pancreas Technology

Read More  

MAIL (2019)

Identifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategy

Read More